AP2A2

AP-2 complex subunit alpha-2 · O94973 · AP2A2 on Sugi Atlas →

0 patent compounds predicted against AP2A2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to AP2A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Baclofen for the Treatment of Alcohol Drinkers PHASE2/PHASE3COMPLETED
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia PHASE1/PHASE2SUSPENDED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study nanCOMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Determination of Maternal and Neonatal Apelinemia in Obese Women During Pregnancy nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
Genetic Study of Schizophrenia nanCOMPLETED
Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome nanRECRUITING
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Genetics of Recurrent Early Onset Major Depression nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Modeling DNA Diversity in Reverse Cholesterol Transport nanCOMPLETED
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia nanCOMPLETED
Bipolar Disorder With Alcoholism in Han Chinese nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a AP2A2 binder may also engage these)

ProteinNameSimilarity
P17427 1.000 P17427 →
P18484 1.000 P18484 →
Q0VCK5 1.000 Q0VCK5 →
AP2A1 AP-2 complex subunit alpha-1 0.985 landscape →
P17426 0.981 P17426 →
Q3TXS7 0.970 Q3TXS7 →
Q5F418 0.968 Q5F418 →
Q80U96 0.968 Q80U96 →
PSMD1 26S proteasome non-ATPase regulatory subunit 1 0.968 landscape →
Q5R5S4 0.968 Q5R5S4 →
GPS1 COP9 signalosome complex subunit 1 0.965 landscape →
Q6NRT5 0.964 Q6NRT5 →
O88761 0.964 O88761 →
XPO1 Exportin-1 0.963 landscape →
Q6P5F9 0.963 Q6P5F9 →
Q66H80 0.962 Q66H80 →
Q3SZA0 0.962 Q3SZA0 →
O55029 0.962 O55029 →
O88544 0.962 O88544 →
Q5R648 0.961 Q5R648 →
DHX9 ATP-dependent RNA helicase A 0.961 landscape →
Q5RA77 0.960 Q5RA77 →
Q5R874 0.959 Q5R874 →
Q68FS2 0.959 Q68FS2 →
ARCN1 Coatomer subunit delta 0.959 landscape →
Q28141 0.959 Q28141 →
Q4R5E6 0.958 Q4R5E6 →
A7Y521 0.958 A7Y521 →
Q99LD4 0.958 Q99LD4 →
O70133 0.958 O70133 →